New combo therapy shows promise for Hard-to-Treat stomach cancer
NCT ID NCT04632459
First seen Jun 10, 2026 · Last updated Jun 16, 2026 · Updated 1 time
Summary
This study tested a combination of two drugs, pembrolizumab and ramucirumab, in 26 people with advanced stomach or gastroesophageal junction cancer that had not responded to other treatments. The goal was to see if the combination could shrink tumors. Participants received the drugs intravenously until their disease worsened or side effects became unacceptable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Samsung Medical Center
Seoul, Seoul, 06351, South Korea
-
Samsung Medical Center
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.